159 related articles for article (PubMed ID: 20563833)
1. Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study.
Mueller S; Polley MY; Lee B; Kunwar S; Pedain C; Wembacher-Schröder E; Mittermeyer S; Westphal M; Sampson JH; Vogelbaum MA; Croteau D; Chang SM
J Neurooncol; 2011 Jan; 101(2):267-77. PubMed ID: 20563833
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
Kunwar S; Chang S; Westphal M; Vogelbaum M; Sampson J; Barnett G; Shaffrey M; Ram Z; Piepmeier J; Prados M; Croteau D; Pedain C; Leland P; Husain SR; Joshi BH; Puri RK;
Neuro Oncol; 2010 Aug; 12(8):871-81. PubMed ID: 20511192
[TBL] [Abstract][Full Text] [Related]
3. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
Kunwar S; Prados MD; Chang SM; Berger MS; Lang FF; Piepmeier JM; Sampson JH; Ram Z; Gutin PH; Gibbons RD; Aldape KD; Croteau DJ; Sherman JW; Puri RK;
J Clin Oncol; 2007 Mar; 25(7):837-44. PubMed ID: 17327604
[TBL] [Abstract][Full Text] [Related]
4. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.
Parney IF; Kunwar S; McDermott M; Berger M; Prados M; Cha S; Croteau D; Puri RK; Chang SM
J Neurosurg; 2005 Feb; 102(2):267-75. PubMed ID: 15739554
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma.
Heiss JD; Jamshidi A; Shah S; Martin S; Wolters PL; Argersinger DP; Warren KE; Lonser RR
J Neurosurg Pediatr; 2018 Dec; 23(3):333-342. PubMed ID: 30544335
[TBL] [Abstract][Full Text] [Related]
6. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
7. MR imaging correlates of survival in patients with high-grade gliomas.
Pope WB; Sayre J; Perlina A; Villablanca JP; Mischel PS; Cloughesy TF
AJNR Am J Neuroradiol; 2005; 26(10):2466-74. PubMed ID: 16286386
[TBL] [Abstract][Full Text] [Related]
8. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
[TBL] [Abstract][Full Text] [Related]
9. Poor drug distribution as a possible explanation for the results of the PRECISE trial.
Sampson JH; Archer G; Pedain C; Wembacher-Schröder E; Westphal M; Kunwar S; Vogelbaum MA; Coan A; Herndon JE; Raghavan R; Brady ML; Reardon DA; Friedman AH; Friedman HS; Rodríguez-Ponce MI; Chang SM; Mittermeyer S; Croteau D; Puri RK;
J Neurosurg; 2010 Aug; 113(2):301-9. PubMed ID: 20020841
[TBL] [Abstract][Full Text] [Related]
10. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.
Kunwar S; Chang SM; Prados MD; Berger MS; Sampson JH; Croteau D; Sherman JW; Grahn AY; Shu VS; Dul JL; Husain SR; Joshi BH; Pedain C; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E15. PubMed ID: 16709020
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma.
Weber F; Asher A; Bucholz R; Berger M; Prados M; Chang S; Bruce J; Hall W; Rainov NG; Westphal M; Warnick RE; Rand RW; Floeth F; Rommel F; Pan H; Hingorani VN; Puri RK
J Neurooncol; 2003; 64(1-2):125-37. PubMed ID: 12952293
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
13. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
[TBL] [Abstract][Full Text] [Related]
14. The influence of intraoperative resection control modalities on survival following gross total resection of glioblastoma.
Neidert MC; Hostettler IC; Burkhardt JK; Mohme M; Held U; Kofmehl R; Eisele G; Woernle CM; Regli L; Bozinov O
Neurosurg Rev; 2016 Jul; 39(3):401-9. PubMed ID: 26860420
[TBL] [Abstract][Full Text] [Related]
15. Impact of extent of resection and recurrent surgery on clinical outcome and overall survival in a consecutive series of 170 patients for glioblastoma in intraoperative high field magnetic resonance imaging.
Coburger J; Wirtz CR; König RW
J Neurosurg Sci; 2017 Jun; 61(3):233-244. PubMed ID: 26149222
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
[TBL] [Abstract][Full Text] [Related]
17. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
18. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
19. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
20. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma.
Weber FW; Floeth F; Asher A; Bucholz R; Berger M; Prados M; Chang S; Bruce J; Hall W; Rainov NG; Westphal M; Warnick RE; Rand RW; Rommell F; Pan H; Hingorani VN; Puri RK
Acta Neurochir Suppl; 2003; 88():93-103. PubMed ID: 14531567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
